The Prognostic Impact of Cytogenetic Scores in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Venetoclax and Azacitidine in a Phase 1 Study

被引：0

作者：

Garcia, Jacqueline S. ^{[1
]}

Wei, Andrew H. ^{[2
,3
]}

Borate, Uma ^{[4
]}

Fong, Chun Yew ^{[5
]}

Baer, Maria R. ^{[6
]}

Nolte, Florian ^{[7
]}

Peterlin, Pierre ^{[8
]}

Jurcic, Joseph ^{[9
]}

Jacoby, Meagan ^{[10
,11
]}

Hong, Wen-Jen ^{[12
]}

Platzbecker, Uwe ^{[13
]}

Odenike, Olatoyosi ^{[14
,15
]}

Cunningham, Ilona ^{[16
]}

Zhou, Ying ^{[17
]}

Dunbar, Martin ^{[17
]}

Harb, Jason G. ^{[17
]}

Popovic, Relja ^{[17
]}

Tanwani, Poonam ^{[17
]}

Gopalakrishnan, Sathej ^{[18
]}

Wolff, Johannes ^{[17
]}

Garcia-Manero, Guillermo ^{[19
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[2] Alfred Hosp, Dept Haematol, Melbourne, Vic, Australia

[3] Monash Univ, Melbourne, Vic, Australia

[4] Oregon Hlth & Sci Univ, Knight Canc Inst, Div Hematol & Med Oncol, Portland, OR 97201 USA

[5] Austin Hlth, Olivia Newton John Canc Res Inst, Melbourne, Vic, Australia

[6] Univ Maryland, Sch Med, Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA

[7] Charite, Dept Hematol & Oncol, Campus Benjamin Franklin, Berlin, Germany

[8] Nantes Univ Hosp, Hematol Dept, Nantes, France

[9] Columbia Univ, Med Ctr, Myelodysplast Syndromes Ctr, New York, NY USA

[10] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO 63110 USA

[11] Washington Univ, Sch Med, St Louis, MO USA

[12] Genentech Inc, San Francisco, CA 94080 USA

[13] Univ Hosp Leipzig, Med Clin & Policlin 1, Hematol & Cellular Therapy, Leipzig, Germany

[14] Univ Chicago Med, Chicago, IL USA

[15] Comprehens Canc Ctr, Chicago, IL USA

[16] Univ Sydney, Concord Clin Sch, Sydney, NSW, Australia

[17] AbbVie Inc, N Chicago, IL USA

[18] AbbVie Deutschland GmbH & Co KG, Wiesbaden, Germany

[19] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷

关键词：

BCL-2; inhibitor; combination therapy; higher-risk MDS; efficacy; MDS; myelodysplastic syndromes;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MDS-141

引用

页码：S315 / S316

页数：2

共 50 条

[41] Final Results From the Phase 2 Continuation Study of the Lenalidomide and Azacitidine Combination in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
Sekeres, Mikkael A.
Komrokji, Rami S.
Lancet, Jeffrey E.
Tiu, Ramon V.
Advani, Anjali S.
Afable, Manual
Englehaupt, Ricki
Juersivich, Joyce
Cuthbertson, David
Paleveda, Jennifer
Paquette, Ronald
Smith, April
Strozniak, Lori
List, Alan F.
Maciejewski, Jaroslaw P.
BLOOD, 2011, 118 (21) : 279 - 279
[42] Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes
Sekeres, Mikkael A.
O'Keefe, Christine
List, Alan F.
Paulic, Katarina
Afable, Manuel, II
Englehaupt, Ricki
Maciejewski, Jaroslaw P.
AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (01) : 102 - 103
[43] Phase 3 VERONA study of venetoclax with azacitidine to assess change in complete remission and overall survival in treatment-naive higher-risk myelodysplastic syndromes.
Zeidan, Amer Methqal
Garcia, Jacqueline Suen
Fenaux, Pierre
Platzbecker, Uwe
Miyazaki, Yasushi
Xiao, Zhi-Jian
Zhou, Ying
Naqvi, Kiran
Kye, Steve
Garcia-Manero, Guillermo
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[44] Phase II Study of Oral Rigosertib Combined With Azacitidine as First-Line Therapy in Patients With Higher-Risk Myelodysplastic Syndromes
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02)
[45] Cytogenetic findings and their prognostic impact in myelodysplastic syndrome patients
Banescu, Claudia
Benedek, Istvan
Duicu, Carmen
Demian, Smaranda
Voidazan, Septimiu
REVISTA ROMANA DE MEDICINA DE LABORATOR, 2011, 19 (02): : 139 - 147
[46] Oral Clofarabine in the Treatment of Patients With Higher-Risk Myelodysplastic Syndrome
Faderl, Stefan
Garcia-Manero, Guillermo
Estrov, Zeev
Ravandi, Farhad
Borthakur, Gautam
Cortes, Jorge E.
O'Brien, Susan
Gandhi, Varsha
Plunkett, William
Byrd, Anna
Kwari, Monica
Kantarjian, Hagop M.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (16) : 2755 - 2760
[47] Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes
Chou, Wen-Chien
Yeh, Su-Peng
Hsiao, Liang-Tsai
Lin, Sheng-Fung
Chen, Yeu-Chin
Chen, Tsai-Yun
Laille, Eric
Galettis, Anoula
Dong, Qian
Songer, Steve
Beach, C. L.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (05) : E430 - E439
[48] PROLONGED SURVIVAL IN HIGHER-RISK MYELODYSPLASTIC SYNDROME (MDS) PATIENTS (PTS) WITH-7/DEL(7Q) TREATED WITH AZACITIDINE (AZA)
Mufti, G. J.
Garcia-Manero, G.
Hovarth, N.
Lim, Z.
Quesnel, B.
Leone, G.
Bennett, J.
Sanz, G.
McKenzie, D.
Backstrom, J.
Beach, C. L.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 369 - 370
[49] A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure
Sebert, Marie
Renneville, Aline
Bally, Cecile
Peterlin, Pierre
Beyne-Rauzy, Odile
Legros, Laurence
Gourin, Marie-Pierre
Sanhes, Laurence
Wattel, Eric
Gyan, Emmanuel
Park, Sophie
Stamatoullas, Aspasia
Banos, Anne
Laribi, Kamel
Jueliger, Simone
Bevan, Luke
Chermat, Fatiha
Sapena, Rosa
Nibourel, Olivier
Chaffaut, Cendrine
Chevret, Sylvie
Preudhomme, Claude
Ades, Lionel
Fenaux, Pierre
HAEMATOLOGICA, 2019, 104 (08) : 1565 - 1571
[50] Oral Clofarabine in the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome
Faderl, Stefan
Garcia-Manero, Guillermo
Estrov, Zeev
Ravandi, Farhad
Borthakur, Gautam
Cortes, Jorge
O'Brien, Susan
Gandhi, Varsha
Plunkett, William
Byrd, Anna L.
Kwari, Monica
Kantarjian, Hagop
BLOOD, 2009, 114 (22) : 53 - 54

← 1 2 3 4 5 →